Bio-Works has confirmed a new order for a customized, prepacked solution worth SEK 0.8 million to be used in a viral vector manufacturing process. The initial order is for process validation runs, and the potential annual revenue from the project is estimated to be between SEK 3-12 million. The customer is an American contract manufacturer of gene therapy products.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.15 SEK | -16.34% |
|
-17.31% | -69.72% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-69.72% | 9.43M | |
-7.03% | 180B | |
-6.32% | 99.21B | |
-6.15% | 66.25B | |
-10.62% | 44.74B | |
+8.34% | 43.82B | |
+10.35% | 41.96B | |
+11.64% | 28.98B | |
+16.18% | 24.07B | |
-8.87% | 23.5B |
- Stock Market
- Equities
- BIOWKS Stock
- News Bio-Works Technologies AB
- Bio-Works Secures SEK 0.8 Million Order for Gene Therapy Manufacturing